The Heart Attack Prevention Checklist. What to Actually Do, in Order.

This is not a wellness list. It is a clinical framework ranked by evidence for cardiovascular event reduction in men over 40 pursuing primary prevention. Each level is ordered by effect size and evidence quality. The items at the top have the strongest data and the largest clinical impact. Items further down are additive and important, but they do not substitute for what comes before them.

Work through it in sequence. The man who completes Level 3 without completing Level 1 has the sequence wrong.

The Mechanism

Atherosclerosis, the pathological process underlying most heart attacks in men over 40, begins decades before the first event. The mechanism is specific: atherogenic lipoprotein particles, primarily LDL and VLDL particles counted by their ApoB protein content, penetrate the arterial intima and are retained there. Retained particles are oxidized, macrophages are recruited, foam cells form, and a plaque begins to accumulate. The process is silent. There are no symptoms from a plaque that is 20 percent, 40 percent, or even 60 percent of vessel diameter. The first symptom is often the rupture of a plaque that was never large enough to cause a stenosis, triggering an acute thrombus that occludes the vessel.

This is why the checklist matters. You cannot feel atherosclerosis developing. You cannot feel your ApoB driving particle penetration into the arterial wall. You cannot feel your blood pressure causing endothelial shear stress that accelerates the process. The measurements are the only way to know what is happening before the acute event provides certainty.

Blood pressure’s mechanism of harm is distinct but parallel. Chronically elevated arterial pressure causes endothelial dysfunction through mechanical shear stress, promotes arterial wall stiffness through smooth muscle hypertrophy, and accelerates the uptake of atherogenic particles at sites of endothelial injury. It also produces left ventricular hypertrophy as the heart compensates for chronically elevated afterload, a remodeling process that raises the risk of arrhythmia and sudden cardiac death independent of coronary disease. The damage from blood pressure that is consistently 145/90 rather than 120/75 accumulates over years without any felt signal.

Insulin resistance connects both processes. Elevated insulin drives hepatic production of small, dense LDL particles that penetrate the arterial wall more readily than larger LDL particles carrying equivalent cholesterol mass. Insulin resistance also promotes visceral fat accumulation, which is metabolically active in a specific inflammatory direction: it secretes IL-6, TNF-alpha, and resistin, all of which worsen endothelial function and drive systemic inflammation. The fasting insulin level is often the earliest measurable indicator of this process, elevated years before HbA1c crosses the diagnostic threshold for prediabetes. A fasting insulin above 15 uIU/mL in a man with a normal glucose and HbA1c is a cardiovascular signal, not a clean result.

What the Evidence Shows

The INTERHEART study (Yusuf et al., Lancet, 2004) is the foundational evidence base for this checklist. Examining more than 27,000 participants across 52 countries using a standardized case-control design, the investigators identified nine modifiable risk factors that together accounted for 90.4 percent of the population-attributable risk for a first myocardial infarction. The five largest: smoking (PAR 35.7%), psychosocial stress (PAR 32.5%), diabetes (PAR 9.9%), hypertension (PAR 17.9%), and abdominal obesity (PAR 20.1%). These are not theoretical contributors. They are the modifiable inputs that, taken together, explain essentially all of the preventable cardiovascular events in men.

The ApoB evidence base is now definitive. Sniderman and colleagues have published extensively demonstrating the superiority of non-HDL cholesterol and ApoB over LDL-C as predictors of cardiovascular events, particularly in individuals with insulin resistance and elevated triglycerides. The European Atherosclerosis Society consensus statement (Borén et al., European Heart Journal, 2020) reviewed over 200 studies and concluded that ApoB is the preferred primary target for atherogenic lipoprotein assessment. This recommendation exists because LDL-C and ApoB diverge substantially in men with metabolic syndrome: a man can have an LDL of 95 mg/dL and an ApoB of 130 mg/dL because insulin resistance shifts the particle distribution toward smaller, more numerous particles. Each particle carries one ApoB and each particle is individually capable of arterial wall penetration. Particle count, not cholesterol mass, is the mechanistic driver.

Coronary artery calcium scoring as a risk reclassification tool has been validated across multiple large prospective cohorts. The Multi-Ethnic Study of Atherosclerosis (Budoff et al., JACC, 2007) demonstrated that a CAC of zero in men at intermediate risk provides a negative predictive value for cardiovascular events exceeding 99 percent over ten years, enabling safe downward reclassification and deferral of statin therapy. A CAC above 100 reclassifies intermediate-risk men to high risk and changes management regardless of other variables. The ACC/AHA 2019 cholesterol guidelines incorporated CAC into the decision pathway explicitly as a tie-breaker when treatment decisions are uncertain. 5 / Solid

Exercise as a cardiovascular intervention has one of the most robust evidence bases in all of preventive medicine. The Aerobics Center Longitudinal Study (Blair et al., JAMA, 1989), following more than 10,000 men over 8 years, found that low cardiorespiratory fitness was a stronger predictor of cardiovascular mortality than smoking, hypertension, or hypercholesterolemia. Subsequent analysis by Myers and colleagues (NEJM, 2002) found each MET increment in exercise capacity associated with a 12 percent reduction in all-cause mortality. The dose-response relationship for aerobic exercise and cardiovascular mortality is one of the most consistent findings in longitudinal epidemiology.

The Holt-Lunstad meta-analysis (Perspectives on Psychological Science, 2015) of 70 prospective studies and more than 3.4 million participants found that social isolation was associated with a 29 percent increase in cardiovascular mortality. This is included in the checklist because it belongs there. The evidence places it alongside hypertension and dyslipidemia in terms of cardiovascular mortality effect size.

Lp(a): The Genetic Risk Variable the Standard Panel Misses

Lipoprotein(a), abbreviated Lp(a), is an LDL-like particle with a structural addition: apolipoprotein(a), a large glycoprotein attached to ApoB via a disulfide bond. This structural feature carries two cardiovascular consequences. First, apolipoprotein(a) contains domains homologous to plasminogen, the protein that dissolves blood clots — making Lp(a) anti-fibrinolytic, impairing clot dissolution at exactly the moment a plaque has ruptured and a thrombus is forming. Second, Lp(a) particles are enriched with oxidized phospholipids, making them more proatherogenic per particle than LDL at equivalent particle counts. The combination of atherogenic lipid delivery, impaired fibrinolysis, and oxidized phospholipid inflammation in a single particle makes Lp(a) mechanistically distinctive.

Clarke and colleagues, reporting in JACC in 2009, conducted a meta-analysis of 36 prospective studies enrolling 126,634 participants and applied Mendelian randomization methodology. Mendelian randomization uses inherited genetic variants that predict Lp(a) concentration to examine whether genetically elevated Lp(a) predicts cardiovascular events — a design that is not confounded by behavioral or lifestyle variables. The conclusion was confirmatory: higher Lp(a) causally increases coronary artery disease risk, with the relationship maintained after adjustment for all traditional cardiovascular risk factors.

Lp(a) concentration is 80 to 90 percent genetically determined through copy number variation in the LPA gene, specifically the kringle IV-2 repeat count. Unlike ApoB, blood pressure, or fasting insulin, Lp(a) does not meaningfully change with diet, exercise, or standard pharmacotherapy. Statins may modestly raise Lp(a) by approximately 10 to 15 percent while simultaneously lowering ApoB — a clinical asymmetry relevant for men treated to ApoB target who still carry unexplained residual risk. Approximately 20 percent of the population carries Lp(a) above the threshold of clinical concern, most commonly defined as 50 mg/dL or 125 nmol/L. Because it is essentially constant across adult life, a single lifetime measurement is sufficient.

The management implications are specific. PCSK9 inhibitors reduce Lp(a) by 25 to 30 percent as a secondary effect beyond their ApoB lowering. RNA-directed therapies specifically targeting Lp(a) production have demonstrated 80 to 90 percent reductions in phase II trials, with cardiovascular event reduction trials currently enrolling. For a man whose ApoB is at target but whose CAC score is disproportionately elevated for his risk profile, or who has a first-degree relative with premature coronary disease, Lp(a) is the measurement most likely to explain the discrepancy. It does not appear on a standard lipid panel and must be requested specifically. 5 / Solid

What to Do This Week

1. Order the Level 1 panel at your next lab visit or as a standalone draw. Request ApoB by name, not just LDL. Request fasting insulin in addition to fasting glucose and HbA1c. Request Lp(a) if it has never been measured; it does not change across a lifetime and needs to be measured only once. These tests require a physician order but are available through most standard labs without specialty referral.

2. Measure your blood pressure at home using a validated device with correct technique: arm at heart level, sitting quietly for five minutes before measuring, two readings per session, seven consecutive mornings. Calculate the average. Do not use a single clinic reading as your blood pressure. The white coat effect and the absence of the reading at 2 a.m. both make the clinic value systematically misleading for the purposes of cardiovascular management.

3. Ask your physician about a coronary artery calcium score if you are between 40 and 65 with any of the following: family history of premature cardiac disease in a first-degree relative, current or prior smoking, blood pressure consistently above 130/80, fasting glucose above 100 mg/dL, or ApoB above 100 mg/dL. The scan is a non-contrast CT, takes approximately ten minutes, and costs $150 to $200 out of pocket where not covered by insurance. A result of zero provides genuine reassurance and changes management. A result above 100 demands treatment regardless of other measurements.

4. Begin 150 minutes per week of moderate aerobic exercise if you are not already there. This is not a lifestyle suggestion. It is the minimum clinically effective dose established by the evidence for cardiovascular mortality reduction. Below this threshold, the cardiovascular adaptation does not fully establish. If you cannot achieve 150 minutes at once, three 50-minute sessions per week is equivalent.

5. Close the loop from measurement to action. Book a follow-up visit specifically to review your numbers against the targets named in this article. Come prepared with the specific question: given these numbers, what is my current cardiovascular risk and what is the plan to bring each measurement to target? That conversation is a cardiovascular management discussion, not a wellness checkup.

The man who completes this checklist and acts on what it shows has taken the most evidence-based steps available for primary prevention of a first cardiac event. Most first myocardial infarctions in men over 40 are not inevitable. They are the consequence of a process that was visible years earlier and that did not receive target-directed management.

Targets and What They Mean

A checklist without targets is incomplete. Here are the specific numbers that define the goal for each item at the top of this list.

ApoB target: Below 80 mg/dL if you have no established cardiovascular disease and are at intermediate or high risk by other measures. Below 65 mg/dL if you have established atherosclerotic cardiovascular disease or are very high risk (prior event, multiple risk factors). These targets come from the 2019 European Atherosclerosis Society consensus statement (Borén et al., European Heart Journal, 2020) and represent the most specific guidance currently available.

Blood pressure target: Below 130/80 mmHg as a home average, based on the SPRINT trial (Wright et al., NEJM, 2015), which found that targeting systolic below 120 mmHg reduced cardiovascular events and all-cause mortality in men at elevated cardiovascular risk compared to the prior standard of below 140 mmHg. The 130/80 target represents the ACC/AHA guideline position that emerged from SPRINT.

Fasting insulin target: Below 7 uIU/mL optimally. A fasting insulin between 7 and 15 uIU/mL indicates early insulin resistance before glucose rises. Above 15 uIU/mL is significant insulin resistance with consequent atherogenic lipid changes. The target is not on the standard lab reference range because most laboratory reference ranges for insulin reflect population distributions rather than metabolic health.

Lp(a) threshold requiring action: Above 50 mg/dL (or 125 nmol/L on molar assays). Above this threshold, Lp(a) independently doubles the risk of cardiovascular events according to Mendelian randomization data and is the basis for the ACC/AHA 2019 recommendation to measure Lp(a) at least once in all adults. Having an Lp(a) above 50 mg/dL does not yet have a specific licensed therapy in most markets, but it demands aggressive management of every other modifiable risk factor that does have treatment.

CAC score thresholds and what they mean:

• Score of 0: Very low event rate over 10 years in asymptomatic men. Does not mean zero risk if major risk factors are present, but enables safe deferral of statin therapy in intermediate-risk men per 2019 ACC/AHA guidelines.
• Score 1 to 99: Increased risk. Treatment decisions depend on overall profile.
• Score 100 and above: High risk. Statin therapy is indicated regardless of LDL-C level per ACC/AHA guidelines.
• Score above 400: Very high risk. Aggressive lipid-lowering to the most stringent targets is warranted.

These are the numbers. The checklist produces them. The clinical conversation applies them to the individual risk profile. That sequence, measurement to target to management, is the work of primary prevention done correctly.